-
Product Insights
Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2018" provides an overview of Pre-Diabetes/Impaired Glucose Tolerance clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Osteoporosis: Global Drug Forecast and Market Analysis to 2027
Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a natural process known as remodeling, some of the bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a “silent”...
-
Sector Analysis
PharmaPoint: Painful Diabetic Neuropathy - Global Drug Forecast and Market Analysis to 2026
Painful diabetic neuropathy is a late-stage complication that occurs in patients suffering from diabetes mellitus and is thought to affect up to half of patients with the disease. PDN manifests itself as a variety of syndromes which differ in clinical course, distribution, fibre involvement and, pathophysiology. Symptoms will vary from patient to patient however; the most common pain symptoms are reported to be numbness, tingling, burning, sharp, and dull/ache-like, which are often localized to the extremities, affecting the feet and...
-
Sector Analysis
Osteoporosis – Global Drug Forecast and Market Analysis to 2027
Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a natural process known as remodeling, some of the bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a “silent”...
-
Sector Analysis
Pompe Disease: Opportunity Analysis and Forecasts to 2027
Pompe disease (PD) is a rare genetic disorder resulting in the accumulation of glycogen with lysosomes in various tissues of the body. It is caused by a multitude of different phenotypical mutations to the GAA gene which is responsible for the transcription of α-glucosidase. α-glucosidase is responsible for glycogen degradation through enzymatic cleavage. PD is characterized by two types: infantile-onset Pomp disease (IOPD) and late-onset Pompe disease (LOPD). IOPD tends to be caused a severe deficiency or entire absence of...
-
Sector Analysis
Diabetic Macular Edema Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM (seven major pharmaceutical markets). The market is forecast to achieve a CAGR of more than 8% during the forecast period. Diabetic Macular Edema is a complication of type 1 and 2 diabetes with diabetic retinopathy. It is a leading cause of visual impairment and blindness in first-world countries, affecting over 28 million people (International Diabetes Federation, 2016; de Moura et al., 2020). The DME research report...
-
Sector Analysis
PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the...
-
Sector Analysis
Hypoglycemia Drug Market Size, Company Share, Trends Analysis and Forecast 2021-2030
The hypoglycemia drug sales have been valued to $423.5 million across the 7MM in 2020 growing at a CAGR of more than 4%. The US has contributed more than 90% of the sales that is primarily due to the significantly higher prices of glucagons in the US, a relatively high diagnosed prevalence of type 1 diabetes (T1D) and high incidence rate of post-bariatric hypoglycemia (PBH). The next largest individual markets are Italy and Germany. Therefore, altogether the 5EU countries make...
-
Sector Analysis
Growth Hormone Deficiency (GHD) - Opportunity Assessment and Forecast
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany and Japan. These therapies are projected to capture over 90% of market share in this region by 2030 due to their potential to improve patient convenience and compliance. Usage of short-acting GHs will markedly decrease over the forecast period as almost all patients switch to treatment with long-acting GHs. These therapies only require...
-
Sector Analysis
Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). This GH excess is often a result of a benign GH-secreting pituitary adenoma. Rarely, tumors in other organs can secrete growth hormone-releasing hormone (GHRH), leading to elevation in GH levels in the serum. This triggers the release of anti-apoptotic and mitogenic peptide hormone, insulin-like growth factor 1 (IGF-1). While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentation of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.